SMOLDERING PLASMA CELL MYELOMA

This study tests whether adding daratumumab to standard lenalidomide and dexamethasone can improve survival in people with high-risk smoldering myeloma, a condition that often progresses to active cancer. About 288 participants will receive either the standard two-drug regimen or…

This phase 2 trial tests iberdomide, an immunotherapy drug, alone or with dexamethasone in 68 people with intermediate- or high-risk smoldering multiple myeloma. The goal is to see if the treatment can shrink or control the cancer cells and delay progression to active myeloma. Pa…

This study looks at whether non-chemo approaches like physical activity, intermittent fasting, or adding a beta-blocker (propranolol) can improve immune function and quality of life in people with multiple myeloma or related blood disorders. Researchers will measure changes in im…

This observational study follows 200 people with early blood conditions (MGUS or smoldering myeloma) that sometimes turn into multiple myeloma. Researchers will track age, blood protein levels, bone marrow cells, genes, and bone health to find patterns that predict progression. N…

This study looks at the quality of life of people with two early blood conditions: MGUS and smoldering myeloma. Researchers will ask 400 participants to fill out short questionnaires about their symptoms and concerns. The goal is to learn what matters most to patients, not to tes…